RedHill Divests Talicia to Apotex for $18M Upfront Plus $35M in Milestones
RDHL is trading near its 52-week low of $0.57 (11% above the low) on light trading volume (0.2× avg).
Summary
RedHill sold its 70% stake in Talicia to Apotex for $18M cash upfront plus up to $35M in milestones — a transformative liquidity event for the micro-cap biopharma.
Key Events · M&A and Partnerships · RDHL
-
Talicia Divestment to Apotex
RedHill sold its 70% interest in Talicia Holdings Inc. to Apotex for $18 million cash upfront plus up to $35 million in potential worldwide net sales milestone payments.
-
Transformative Liquidity Infusion
The $18M upfront payment is approximately 4.5x RedHill's entire market cap of ~$4M, immediately strengthening liquidity and funding the next phase of commercial expansion.
-
Non-Compete and Transition Services
RedHill agreed to a five-year non-compete covenant for Talicia in the U.S. and will provide transition services for 6 months, extendable by 3 months for limited services.
-
Strategic Repositioning
Proceeds are intended to fund new, high-value FDA-approved product opportunities in the GI franchise and accelerate the path toward operational profitability.
Analysis · RDHL · Life Sciences
RedHill is selling its 70% stake in Talicia Holdings to Apotex for $18 million in cash upfront, with up to $35 million more in potential milestone payments. For a company with a market cap around $4 million, this is a transformative liquidity event — the upfront cash alone is roughly 4.5x the company's entire market value. The deal converts a shared-ownership asset into immediate capital, directly addressing the going-concern and delisting warnings that have plagued RedHill. The five-year non-compete and transition services agreement show Apotex is getting full control of the product, while RedHill gets runway to pursue its GI franchise expansion.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.8% of the 571 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDHL was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.57 to $2.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.